Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Rigel (RIGL) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Olutasidenib, Cyp1a2, Cyp2b6, Cyp2c8, Cyp2c9, Cyp2c19, Cyp3a4, And Oatp1b1 Probe SubstratesGlioma, Solid Tumor Malignancies, Cholangiocarcinoma, Aml (Acute Myeloid Leukemia)Phase IVRecruitingOlutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesMar 12, 2026―
Olutasidenib + TmzHigh Grade Glioma, Astrocytoma, Astrocytoma, Grade Iii, Astrocytoma, Grade Iv, Diffuse Intrinsic Pontine Glioma, Who Grade Iii Glioma, Who Grade Iv Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27m-Mutant, Thalamus Tumor, Spinal Tumor, Idh1 Mutation, Idh1 R132, Idh1 R132c, Idh1 R132h, Idh1 R132s, Idh1 R132g, Idh1 R132l, OligodendrogliomaPhase IIRecruitingStudy of Olutasidenib and Temozolomide in HGGNov 22, 2023―
Ly3871801Rheumatoid ArthritisPhase IIRecruitingAn Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisApr 28, 2023
R906289 MonosodiumLow Risk Myelodysplastic Syndromesphase1AndPhase2RecruitingStudy of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)Mar 02, 2022―
FostamatinibCOVID19, Pneumonia, Pneumonia, Viral, Sars (Severe Acute Respiratory Syndrome), Sars Pneumonia, Sars-Associated Coronavirus As Cause Of Disease Classified ElsewherePhase IIICompletedDouble-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 SubjectsNov 13, 2020―
Fostamatinib DisodiumWarm Antibody Autoimmune Hemolytic AnemiaPhase IIIEnrolling By InvitationA Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaOct 23, 2019―
Fostamatinib DisodiumWarm Antibody Autoimmune Hemolytic AnemiaPhase IIICompletedA Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHADec 03, 2018―
Fostamatinib 150 Mg BidWarm Antibody Autoimmune Hemolytic AnemiaPhase IICompletedA Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)Nov 19, 2015―
Fostamatinib Disodium Tablet 100 Mg, Fostamatinib Disodium Tablet 150 MgIga NephropathyPhase IIWithdrawnOpen Label Study of Fostamatinib in the Treatment of IgA NephropathyApr 29, 2015―
Fostamatinib 150 Mg, Fostamatinib 100 MgIga NephropathyPhase IICompletedSafety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyApr 10, 2014―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Rigel Pharmaceuticals (RIGL) have in its pipeline
Rigel RIGL is currently developing the following drugs: Olutasidenib, Cyp1a2, Cyp2b6, Cyp2c8, Cyp2c9, Cyp2c19, Cyp3a4, And Oatp1b1 Probe Substrates, Olutasidenib + Tmz, Ly3871801, R906289 Monosodium, Fostamatinib, Fostamatinib Disodium, Fostamatinib 150 Mg Bid, Fostamatinib Disodium Tablet 100 Mg, Fostamatinib Disodium Tablet 150 Mg, Fostamatinib 150 Mg, Fostamatinib 100 Mg, R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R932333, R940343 1Mg, R940343 2Mg, Fostamatinib Disodium / R935788. These drug candidates are in various stages of clinical development as the company works toward FDA approval.